The severe side effects of systemic high doses of chemotherapy, as well as the development of drug resistance, make anticancer therapy less safe and effective. Pain, cardiotoxicity, hepatotoxicity, and renal toxicity are all adverse effects of traditional chemotherapy [1,2]. As a result, novel strategies for improving anticancer medication therapeutic index by targeted administration to tumor locations are constantly being researched and developed. Among a variety of options, hydrogels are a potential option because they can be made up of smart materials that respond to environmental influences and change their characteristics appropriately, allowing for targeted drug delivery [3]. Injectable thermosensitive hydrogels for drug delivery have been extensively studied [4]. Thermosensitive hydrogels are a type of drug delivery system that is liquid at the moment of administration. This paper reports on a the synthesis of a temperature-responsive hydrogel for the controlled release of BAMLET, a complex of bovine alpha-lactalbumin and oleic acid, as a model anticancer drug. BAMLET was originally isolated from bovine milk as a potent anticancer agent. It kills a wide range of cancerous cells of various origins while leaving healthy cells largely unaffected both in vitro and in vivo. Poly(N-isopropylacrylamide) polymer as a thermoresponsive hydrogel was synthesized via the free-radical polymerization method. The formulation of the BAMLET-Hydrogel was optimized and the following values were used as the optimum: 10% w/w polymer, 50 L of the drug, and phosphate buffer of pH 7. Under the optimized conditions the cloud point, lower critical solution temperature, and the swelling ratio of the formulation were 26 C, 30 C, and 2.6 (at 37 C), respectively. In vitro release experiments showed that BAMLET was slowly released from the formulation. Therefore, BAMLET-loaded thermosensitive hydrogel based on poly(N-isopropylacrylamide) polymer is a promising sustainable delivery system fo
